KDIDFLIEEIER-
LGQDL corresponding to the C-terminal region of
GAD 67 of human origin (amino acids 579-594 with
N-terminally added lysine) as immunogen. This
sequence is identical in human GAD 65 (amino
biosensors.
Biosens. Bioelectron., 14(6), 579-585 (1999).
5. Riboni, L., et al., A fast staining method for CNS
slices. J. Neurosci. Methods, 38(2-3), 239-241
(1991).
6. Matsui, S., et al
biosensors.
Biosens. Bioelectron., 14(6), 579-585 (1999).
5. Riboni, L., et al., A fast staining method for CNS
slices. J. Neurosci. Methods, 38(2-3), 239-241
(1991).
6. Matsui, S., et al
DNA-protein interactions. The
regulation of poly(ADP-ribose) polymerase. Eur. J.
Biochem., 127, 579-85 (1982).
2. Giner, H., et al., Overproduction and large-scale
purification of the human poly(ADP-ribose
578 (1968)
2. S. King, W.I. Metzger, A new plating medium for the isolation of enteric pathogens. II.
Comparison of Hektoen Enteric Agar with SS and EMB Agar, Appl. Microbiol. 16, 579-581(1968)
Nattel, S. and Singh, B. N., Am. J. Cardiol., 84, 11R
(1999).
14. Singh, V. et al., Drugs, 58, 579 (1999).
15. Rodnitzky, R. L., Drugs, 57, 845 (1999).
16. Westenbroek, R. E., et al., J.
Nattel, S. and Singh, B.N., Am. J. Cardiol., 84, 11R
(1999).
13. Singh, V. et al., Drugs, 58, 579 (1999).
14. Rodnitzky, R.L., Drugs, 57, 845 (1999).
15. Shistik, E. et al., J. Biol. Chem., 274, 31145
Nattel, S. and Singh, B.N., Am. J. Cardiol., 84, 11R
(1999).
12. Singh, V. et al., Drugs, 58, 579 (1999).
13. Rodnitzky, R. L., Drugs, 57, 845 (1999).
14. Westenbroek, R. E., et al., J.
Nattel, S. and Singh, B.N., Am. J. Cardiol., 84, 11R
(1999).
16. Singh, V. et al., Drugs, 58, 579 (1999).
17. Rodnitzky, R. L., Drugs, 57, 845 (1999).
18. Westenbroek, R.E., et al., J. Neurosci
Committee for the
Prevention, Detection, Evaluation and Treatment of
High Blood Pressure., Drugs, 58, 579 (1999).
15. Rodnitzky, R.L., Can calcium antagonists provide a
neuroprotective effect in Parkinson's
using a synthetic phosphorylated peptide derived from
the region of human Pyk2 that contains tyrosine 579 as
immunogen. The antiserum is affinity purified using
epitope-specific affinity chromatography.
Committee for the
Prevention, Detection, Evaluation and Treatment of
High Blood Pressure., Drugs, 58, 579-87 (1999).
16. Rodnitzky, R.L., Can calcium antagonists provide a
neuroprotective effect in Parkinson's
supply frequency 50 – 60 Hz ± 10%
Feed water connection 1/2 in. Gaz F
Data connection Ethernet (RJ45)
Q-POD® accessory dimensions
Parameter Value & Unit
Q-POD® height 579 mm (23.50 in.)
Q-POD
., The appearance of acute phase
protein in various diseases. Acta Med. Scand.,
128(Suppl. 196), 579-601 (1947).
9. Morley, J.J., and Kushner, I., Serum C-reactive
Protein Levels. in C-Reactive Protein
Pyk2 P3902 Signal Transduction P y y y
219 Pyk2 Phospho (pY
579) P7114 Signal Transduction P y n/d y
220 Pyk2 Phospho (pY
579/580) P6989 Signal Transduction P y n/d n/d
221 Pyk2
618 565 539 494 497
607 579 528 390 561 580
534 475 427 511 434 671
3
Transwell Assay
This protocol is designed to assess drug transporter
functionality in Caco-2 cells. The experiment
618 565 539 494 497
607 579 528 390 561 580
534 475 427 511 434 671
Transwell Assay:
This protocol is designed to assess drug transporter
functionality in Caco-2 cells. Transport is measured
507
610 618 565 539 494 497
607 579 528 390 561 580
534 475 427 511 434 671
Transwell Assay
This protocol is designed to assess drug transporter
functionality in Caco-2 cells. The experiment must
include
507
610 618 565 539 494 497
607 579 528 390 561 580
534 475 427 511 434 671
Transwell Assay
This protocol is designed to assess drug transporter
functionality in Caco-2 cells. The experiment must
include
507
610 618 565 539 494 497
607 579 528 390 561 580
534 475 427 511 434 671
Transwell Assay
This protocol is designed to assess drug transporter
functionality in Caco-2 cells. The experiment must
include
507
610 618 565 539 494 497
607 579 528 390 561 580
534 475 427 511 434 671
Transwell Assay
This protocol is designed to assess drug transporter
functionality in Caco-2 cells. The experiment must
include
507
610 618 565 539 494 497
607 579 528 390 561 580
534 475 427 511 434 671
Transwell Assay
This protocol is designed to assess drug transporter
functionality in Caco-2 cells. The experiment must
include
507
610 618 565 539 494 497
607 579 528 390 561 580
534 475 427 511 434 671
Transwell Assay
This protocol is designed to assess drug transporter
functionality in Caco-2 cells. The experiment must
include